编者按：2025年欧洲肿瘤内科学会乳腺癌年会（ESMO ...

The risk of cardiotoxicity may vary across CDK4/6 inhibitors, according to a study of patients with breast cancer published in the Journal of the National Comprehensive Cancer Network.

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 ...

Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease.

Breast cancer deaths among women ages 20-49 declined significantly between 2010 and 2020, according to a new study.

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...